Featured stories
- 09-07-2020 LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis
- 30-06-2020 LEO Pharma strengthens global leadership team
- 15-04-2020 LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate
- 13-03-2020 Updates regarding COVID-19
- 02-03-2020 LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma
- 27-02-2020 With topline growth of 7% in 2019, margin improvements and pipeline success, LEO Pharma paves the way for an ambitious future
- 09-01-2020 LEO Pharma initiates voluntary withdrawal of marketing authorization and possible voluntary withdrawal of Picato® in the EU and EEA. Marketing of Picato® continues in US and elsewhere
- 23-12-2019 LEO Pharma Signs Agreement to Divest Emollients and Proctology Portfolio to Karo Pharma
- 11-12-2019 LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD
- 04-12-2019 LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device
- 21-11-2019 LEO Pharma launches Open Innovation in Ontario to support the innovation ecosystem in the province
- 19-11-2019 LEO Pharma launches Open Innovation program and partnership with the University of Victoria in Canada
- 14-11-2019 Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
- 12-11-2019 LEO Pharma exercises option with HitGen to license compounds for development of novel class of drugs in dermatology
- 07-11-2019 LEO Science & Tech Hub and Epicore Biosystems Announce Second Phase of Partnership
- 30-10-2019 LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds
- 24-10-2019 World Psoriasis Day 2019: LEO Pharma launches new campaign to reduce the stigma surrounding psoriasis
- 01-07-2019 LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
- 03-06-2019 LEO Pharma appoints Catherine Mazzacco as new CEO
- 10-05-2019 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
- 11-04-2019 LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
- 09-04-2019 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
- 19-03-2019 LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
LEADERSHIP
Meet our Global Leadership Team
The Global Leadership Team is responsible for overall business growth, strategic direction and daily operations.
MEDIA TOOLKIT
We pursue an open and active dialogue with the media
We believe in making our activities and operations accessible to all relevant media
MEDIA ENQUIRIES
